Tirzepatide May Lower Risk of Diabetic Retinopathy

New research suggests a potential benefit for individuals managing type 2 diabetes: medications like Mounjaro and Zepbound, containing the active ingredient tirzepatide, may lower the risk of developing diabetic retinopathy. This complication of diabetes occurs when high blood sugar levels damage blood vessels in the retina, potentially leading to vision loss.

Tirzepatide and Eye Health: What the Study Found

Researchers analysed electronic health records from a substantial cohort of 174,000 people across 70 health systems in the United States. The study focused on individuals with type 2 diabetes and weight management concerns, comparing those who began taking tirzepatide to those pursuing lifestyle interventions like nutrition therapy or exercise counseling. After one year, those taking tirzepatide demonstrated a lower risk of worsening diabetic retinopathy or experiencing related complications.

Previous Concerns and Current Findings

Prior research indicated that weight loss medications, including Ozempic and Wegovy, could worsen diabetic retinopathy. However, a previous study involving semaglutide medications found that any deterioration was temporary, with no long-term association between the medication and increased progression of the eye disease over a three-year period.

Did You Know? A 2021 study estimated that nearly 10 million people in the United States have diabetic retinopathy, with approximately 2 million cases being vision-threatening.

How Tirzepatide May Offer Protection

According to Szilard Kiss, MD, an ophthalmologist at NewYork-Presbyterian/Weill Cornell Medical Center and lead author of the study, the findings suggest that individuals with diabetic retinopathy may be less concerned about the medication worsening their condition. He also noted a potential reduction in the need for more intensive eye treatments, such as laser therapy or injections, typically required in severe cases.

Both tirzepatide and semaglutide medications work by mimicking the body’s natural GLP-1 hormone, suppressing appetite and aiding in blood sugar management. Adrian Au, MD, an ophthalmologist at UCLA Health, explained that reducing blood sugar levels is a key factor in mitigating diabetic retinopathy, though some temporary risks may exist.

Benjamin Bert, MD, an ophthalmologist at MemorialCare Orange Coast Medical Center, suggested a simple explanation: tirzepatide’s effects on diabetic retinopathy may be linked to its ability to improve insulin sensitivity, promote weight loss, and reduce metabolic inflammation.

Expert Insight: While these findings are encouraging, it’s important to remember that this study demonstrates an association, not definitive proof of cause and effect. Further research is needed to fully understand the long-term impact of tirzepatide on diabetic retinopathy.

Looking Ahead

The study’s findings are preliminary, and researchers caution that observational data only shows association, not causation. If these findings are confirmed in further studies, it could lead to a shift in how doctors and patients weigh the risks and benefits of tirzepatide for individuals with type 2 diabetes and existing diabetic retinopathy.

It is also possible that continued research will reveal more about the optimal timing and monitoring strategies for patients starting tirzepatide, particularly those with pre-existing eye disease.

Frequently Asked Questions

What is diabetic retinopathy?

Diabetic retinopathy is an eye condition that can develop in people with type 1 or type 2 diabetes. It occurs when high blood sugar damages the blood vessels in the retina.

What are the symptoms of diabetic retinopathy?

In the early stages, diabetic retinopathy often causes no symptoms. When symptoms do occur, they can include mild vision problems.

How is diabetic retinopathy treated?

Treatments for diabetic retinopathy typically focus on managing blood sugar and overall health. These treatments include injections, laser treatments, and surgery.

What role do you think lifestyle factors, in addition to medication, play in managing diabetic retinopathy?